• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting Continued Growth with Record Q1 Net Revenue of $210 Million and Net Income

    10/9/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email

    Operational Efficiencies and Focus on Profitability Drove Net Income of $1.5 Million, Adjusted EBITDA Increased 9% to $10 Million and Net Cash Used in Operations Improved by $34 Million Year-Over-Year

    Canadian Adult-Use Cannabis Gross Revenue Increased 12%, Maintaining the #1 Position in Revenue and Expanding Market Share; International Cannabis Revenue Grew 10% Year-Over-Year

    Balance Sheet Strengthened to $265 Million in Cash; Net Debt Reduced to $4 Million

    Reiterates Fiscal Year 2026 Adjusted EBITDA Outlook of $62 Million – $72 Million

    NEW YORK and LONDON and LEAMINGTON, Ontario, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today reported financial results for its first fiscal quarter ended August 31, 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

    Irwin D. Simon, Chairman and Chief Executive Officer, stated, "As we enter fiscal 2026, Tilray's first quarter results underscore the effectiveness of our strategic vision and disciplined execution. Achieving a record Q1 net revenue of $210 million, delivering net income, and fortifying our balance sheet are not just milestones, they are proof points of our commitment to building sustainable growth, operational excellence, and unlocking value for our shareholders. Our global platform positions Tilray Brands not just to participate in, but to lead, the evolution of the global cannabis, beverage, and wellness sectors."

    Mr. Simon continued, "Looking forward, I am confident in Tilray's ability to seize the transformative opportunities ahead, especially as the U.S. explores cannabis rescheduling and the European cannabis landscape continues to evolve. Our global platform, proven expertise in medical and adult-use cannabis, and trusted partnerships with patients, healthcare professionals, and policymakers set us apart as the partner of choice in this dynamic industry. We are committed to expanding access, advancing innovation, and supporting responsible regulatory progress around the world. These achievements and forward trends reinforce my unwavering belief in Tilray's trajectory and our ability to deliver long-term value to our investors."

    Financial Highlights

    All comparisons made to the prior year period

    • Net revenue increased 5% to $209.5 million in the first quarter compared to $200.0 million.
    • Gross profit was $57.5 million in the first quarter compared to $59.7 million.
    • Gross margin was 27% in the first quarter compared to 30%.
    • Cannabis net revenue increased 5% to $64.5 million in the first quarter compared to $61.2 million.
      • Cannabis gross profit was $23.3 million in the first quarter compared to $24.2 million.
      • Cannabis gross margin was 36% in the first quarter compared to 40%.
    • Beverage net revenue was $55.7 million in the first quarter compared to $56.0 million.
      • Beverage gross profit was $21.3 million in the first quarter compared to $22.9 million.
      • Beverage gross margin was 38% in the first quarter compared to 41%.
    • Wellness net revenue increased to $15.2 million in the first quarter compared to $14.8 million.
      • Wellness gross margin was 32% in the first quarter and was unchanged.
    • Distribution net revenue was $74.0 million in the first quarter compared to $68.1 million.
      • Distribution gross margin was 11% in the first quarter compared to 12%.
    • Net income was $1.5 million in the first quarter compared to a net loss of $(34.7) million.
    • Adjusted net income increased by $10.0 million to $3.9 million in the first quarter compared to adjusted net loss of $(6.1) million.
    • Adjusted EBITDA increased 9% to $10.2 million in the first quarter compared to $9.3 million.

    Cash Flow: Cash used in operations improved significantly by $34.0 million to $(1.3) million from $(35.3) million.

    Balance Sheet Update: In the first quarter, Tilray reduced its total outstanding debt by $7.7 million, further strengthening the balance sheet. As a result, the ratio of net debt to trailing twelve months adjusted EBITDA was reduced to 0.07x. Our $264.8 million cash balance provides Tilray with great flexibility for strategic opportunities.



    Live Audio Webcast

    Tilray Brands will host a webcast to discuss these results today at 8:30 a.m. Eastern Time. Investors may join the live webcast available on the Events & Presentations section of Tilray's Investor Relations website. A replay will be available and archived on the Company's website.

    About Tilray Brands



    Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

    For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

    Cautionary Statement Concerning Forward-Looking Statements

    Certain statements in this press release constitute forward-looking information or forward-looking statements (together, "forward-looking statements") under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements can be identified by words such as "forecast," "future," "should," "could," "enable," "potential," "contemplate," "believe," "anticipate," "estimate," "plan," "expect," "intend," "position," "may," "project," "will," "would" and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.

    Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company's ability to become a leading lifestyle consumer packaged goods company; the Company's ability to become a leading beverage alcohol Company; the Company's ability to achieve long term profitability; the Company's ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company's ability to successfully achieve revenue growth, margin and profitability improvements, production and supply chain efficiencies, synergies and cost savings; the Company's ability to achieve fiscal year 2026 financial guidance, including expected Adjusted EBITDA of $62 to $72 million and synergy optimizations; the Company's expected revenue growth, sales volume, profitability, synergies and accretion related to any of its acquisitions; expected opportunities in the U.S., including upon U.S. federal cannabis legalization or rescheduling; the Company's ability to successfully leverage artificial intelligence strategies; the Company's anticipated investments and acquisitions, including in organic and strategic growth, partnership efforts, product offerings and other initiatives; and the Company's ability to commercialize new and innovative products.

    Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

    Use of Non-U.S. GAAP Financial Measures

    This press release and the accompanying tables include non-GAAP financial measures, including Adjusted gross margin (consolidated and for each of our reporting segments), Adjusted gross profit (consolidated and for each of our reporting segments), Adjusted EBITDA, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, adjusted free cash flow, constant currency presentations of revenue, cash and marketable securities, net debt and net debt to adjusted EBITDA. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company's operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company's Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.

    Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company's GAAP financial results.

    The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company's consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year. A reconciliation of prior year revenue to constant currency revenue the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

    Adjusted EBITDA is calculated as net income (loss) before income tax benefits, net; interest expense, net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; project 420 optimization costs; litigation costs; restructuring costs, and transaction (income) costs, net. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.

    Adjusted net income (loss) is calculated as net loss attributable to stockholders of Tilray Brands, Inc., less; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent project 420 optimization costs; litigation costs; restructuring costs and transaction (income) costs, net. A reconciliation of Adjusted net income (loss) to net loss attributable to stockholders of Tilray Brands, Inc., the most directly comparable GAAP measure, has been included below in this press release.

    Adjusted net income (loss) per share is calculated as net loss attributable to stockholders of Tilray Brands, Inc., net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; project 420 optimization costs; litigation costs; restructuring costs and transaction (income) costs, divided by weighted average number of common shares outstanding. A reconciliation of Adjusted net income (loss) per share to net loss attributable to stockholders of Tilray Brands, Inc., the most directly comparable GAAP measure, has been included below in this press release. Adjusted net income (loss) per share is not calculated in accordance with GAAP and should not be considered an alternative for GAAP net income (loss) per share or as a measure of liquidity.

    Adjusted gross profit (consolidated and for each of our reporting segments), is calculated as gross profit adjusted to exclude the impact of purchase price accounting valuation step-up. A reconciliation of Adjusted gross profit, excluding purchase price accounting valuation step-up, to gross profit, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release. Adjusted gross margin (consolidated and for each of our reporting segments), excluding purchase price accounting valuation step-up, is calculated as revenue less cost of sales adjusted to add back amortization of inventory step-up, divided by revenue. A reconciliation of Adjusted gross margin, excluding purchase price accounting valuation step-up, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

    Free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release. Adjusted free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net, and the exclusion of growth CAPEX from investments in capital and intangible assets, net, which excludes the amount of capital expenditures that are considered to be associated with growth of future operations rather than to maintain the existing operations of the Company, and excludes cash paid for litigation settlements. A reconciliation of net cash flow provided by (used in) operating activities to adjusted free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

    Cash and marketable securities are comprised of two GAAP measures, cash and cash equivalents added to marketable securities. The Company's management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combing these two GAAP metrics.

    Net debt is comprised of GAAP measures and reduces bank indebtedness, current and non-current portions of long-term debt, the principal balance of convertible debt by cash and cash equivalents and marketable securities. The company believes this metric provides useful information to management, analysts, and investors regarding its liquidity and the Company's ability to repay all of its debt. Net debt to adjusted EBITDA is a liquidity ratio used by management and is computed as the ratio of net debt to the trailing 12 months of adjusted EBITDA defined above.

    Contacts:

    Investor Relations

    [email protected]

    [email protected]

    Media

    [email protected]



         
    Consolidated Statements of Financial Position    
      August 31, May 31,
    (in thousands of US dollars)  2025   2025 
    Assets    
    Current assets    
    Cash and cash equivalents $264,828  $221,666 
    Marketable securities  —   34,697 
    Accounts receivable, net  107,075   121,489 
    Inventory  282,787   270,882 
    Prepaids and other current assets  40,650   34,092 
    Assets held for sale  5,800   5,800 
    Total current assets  701,140   688,626 
    Capital assets  560,157   568,433 
    Operating lease, right-of-use assets  21,003   22,279 
    Digital assets  992   — 
    Intangible assets  25,173   21,423 
    Goodwill  752,350   752,350 
    Long-term investments  10,172   10,132 
    Other assets  11,659   11,084 
    Total assets $2,082,646  $2,074,327 
    Liabilities    
    Current liabilities    
    Bank indebtedness $8,185  $7,181 
    Accounts payable and accrued liabilities  230,913   235,322 
    Contingent consideration  —   15,000 
    Warrant liability  4,762   1,092 
    Current portion of lease liabilities  7,477   6,941 
    Current portion of long-term debt  16,295   14,767 
    Total current liabilities  267,632   280,303 
    Long - term liabilities    
    Lease liabilities  63,345   64,925 
    Long-term debt  144,175   148,493 
    Convertible debentures payable  84,267   86,428 
    Deferred tax liabilities, net  1,943   3,748 
    Other liabilities  626   855 
    Total liabilities  561,988   584,752 
    Stockholders' equity    
    Common stock ($0.0001 par value; 1,416,000,000 common shares authorized; 1,118,291,159 and 1,060,678,745 common shares issued and outstanding, respectively)  111   106 
    Treasury Stock (3,213,914 and 2,004,218 treasury shares issued and outstanding, respectively)  —   — 
    Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively)  —   — 
    Additional paid-in capital  6,431,410   6,401,657 
    Accumulated other comprehensive loss  (43,230)  (43,063)
    Accumulated deficit  (4,847,548)  (4,847,226)
    Total Tilray Brands, Inc. stockholders' equity  1,540,743   1,511,474 
    Non-controlling interests  (20,085)  (21,899)
    Total stockholders' equity  1,520,658   1,489,575 
    Total liabilities and stockholders' equity $2,082,646  $2,074,327 
         





    Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)

      For the three months ended    
      August 31, August 31, Change % Change
    (in thousands of U.S. dollars, except for per share data)  2025   2024  2025 vs. 2024
    Net revenue $209,501  $200,044  $9,457  5%
    Cost of goods sold  152,032   140,338   11,694  8%
    Gross profit  57,469   59,706   (2,237) (4)%
    Operating expenses:        
    General and administrative  41,053   44,113   (3,060) (7)%
    Selling  12,923   11,690   1,233  11%
    Amortization  3,929   21,804   (17,875) (82)%
    Marketing and promotion  10,155   11,566   (1,411) (12)%
    Research and development  41   105   (64) (61)%
    Change in fair value of contingent consideration  (15,000)  —   (15,000) NM
    Litigation costs, net of recoveries  1,007   1,595   (588) (37)%
    Restructuring costs  869   4,247   (3,378) (80)%
    Transaction costs (income), net  400   1,156   (756) (65)%
    Total operating expenses  55,377   96,276   (40,899) (42)%
    Operating income (loss)  2,092   (36,570)  38,662  (106)%
    Interest expense, net  (6,696)  (9,842)  3,146  (32)%
    Non-operating income (expense), net  3,832   12,646   (8,814) (70)%
    Loss before income taxes  (772)  (33,766)  32,994  (98)%
    Income tax expense (recovery), net  (2,285)  886   (3,171) (358)%
    Net income (loss) $1,513  $(34,652) $36,165  (104)%
    Total net income (loss) attributable to:        
    Stockholders of Tilray Brands, Inc.  (322)  (39,165)  38,843  (99)%
    Non-controlling interests  1,835   4,513   (2,678) (59)%
    Other comprehensive gain (loss), net of tax        
    Foreign currency translation gain (loss)  (188)  4,160   (4,348) (105)%
    Comprehensive income (loss) $1,325  $(30,492) $31,817  (104)%
    Total comprehensive income (loss) attributable to:        
    Stockholders of Tilray Brands, Inc.  (322)  (39,165)  38,843  (99)%
    Non-controlling interests  1,835   4,513   (2,678) (59)%
    Weighted average number of common shares - basic  1,060,271,899   875,444,828   184,827,071  21%
    Weighted average number of common shares - diluted  1,060,271,899   875,444,828   184,827,071  21%
    Net loss per share - basic $(0.00) $(0.04) $0.04  (100)%
    Net loss per share - diluted $(0.00) $(0.04) $0.04  (100)%
             





    Condensed Consolidated Statements of Cash Flows

      For the three months ended    
      August 31, August 31, Change % Change
    (in thousands of US dollars)  2025   2024  2025 vs. 2024
    Cash provided by (used in) operating activities:        
    Net income (loss) $1,513  $(34,652) $36,165  (104)%
    Adjustments for:        
    Deferred income tax (recovery) expense, net  (2,285)  382   (2,667) (698)%
    Unrealized foreign exchange gain  (2,328)  (5,602)  3,274  (58)%
    Amortization  15,561   31,814   (16,253) (51)%
    Accretion of convertible debt discount  1,976   3,067   (1,091) (36)%
    Unrealized loss on digital assets  8   —   8  NM
    Other non-cash items  282   729   (447) (61)%
    Stock-based compensation  5,052   6,917   (1,865) (27)%
    Gain on long-term investments  (39)  (499)  460  (92)%
    Loss (gain) on derivative instruments  3,670   (696)  4,366  (627)%
    Change in fair value of contingent consideration  (15,000)  —   (15,000) NM
    Change in non-cash working capital:        
    Accounts receivable  14,414   (2,342)  16,756  (715)%
    Prepaids and other current assets  (7,133)  (13,570)  6,437  (47)%
    Inventory  (11,905)  (12,383)  478  (4)%
    Accounts payable and accrued liabilities  (5,127)  (8,472)  3,345  (39)%
    Net cash used in operating activities  (1,341)  (35,307)  33,966  (96)%
    Cash provided by (used in) investing activities:        
    Investment in capital and intangible assets  (9,523)  (6,736)  (2,787) 41%
    Proceeds from disposal of capital and intangible assets  293   28   265  946%
    Investment in digital assets  (1,000)  —   (1,000) NM
    Disposal (purchase) of marketable securities, net  34,697   (42,687)  77,384  (181)%
    Net cash provided by (used in) investing activities  24,467   (49,395)  73,862  (150)%
    Cash provided by (used in) financing activities:        
    Share capital issued, net of cash issuance costs  22,491   66,472   (43,981) (66)%
    Repayment of long-term debt  (2,653)  (4,791)  2,138  (45)%
    Repayment of convertible debt  —   (330)  330  (100)%
    Repayment of lease liabilities  (994)  (862)  (132) 15%
    Net decrease in bank indebtedness  1,004   101   903  894%
    Net cash provided by financing activities  19,848   60,590   (40,742) (67)%
    Effect of foreign exchange on cash and cash equivalents  188   958   (770) (80)%
    Net increase (decrease) in cash and cash equivalents  43,162   (23,154)  66,316  (286)%
    Cash and cash equivalents, beginning of period  221,666   228,340   (6,674) (3)%
    Cash and cash equivalents, end of period $264,828  $205,186  $59,642  29%
             





    Net Revenue by Operating Segment

      For the three months ended For the three months ended
    (In thousands of U.S. dollars) August 31, 2025 % of Total

    Revenue
     August 31, 2024 % of Total

    Revenue
    Beverage business $55,739  27% $55,972  28%
    Cannabis business  64,511  31%  61,249  31%
    Distribution business  74,007  35%  68,071  34%
    Wellness business  15,244  7%  14,752  7%
    Total net revenue $209,501  100% $200,044  100%
             
    Net Revenue by Operating Segment in Constant Currency

      For the three months ended For the three months ended
      August 31, 2025   August 31, 2024  
    (In thousands of U.S. dollars) as reported in

    constant currency
     % of Total

    Revenue
     as reported in

    constant currency
     % of Total

    Revenue
    Beverage business $55,739  27% $55,972  28%
    Cannabis business  64,049  31%  61,249  31%
    Distribution business  69,706  34%  68,071  34%
    Wellness business  15,281  8%  14,752  7%
    Total net revenue $204,775  100% $200,044  100%
             
    Net Cannabis Revenue by Market Channel

      For the three months ended For the three months ended
    (In thousands of U.S. dollars) August 31, 2025 % of Total

    Revenue
     August 31, 2024 % of Total

    Revenue
    Revenue from Canadian medical cannabis $6,146  10% $6,261  10%
    Revenue from Canadian adult-use cannabis  64,067  99%  57,235  94%
    Revenue from wholesale cannabis  4,155  6%  5,507  9%
    Revenue from international cannabis  13,367  21%  12,191  20%
    Less excise taxes  (23,224) (36)%  (19,945) (33)%
    Total $64,511  100% $61,249  100%
             
    Net Cannabis Revenue by Market Channel in Constant Currency

      For the three months ended For the three months ended
      August 31, 2025   August 31, 2024  
    (In thousands of U.S. dollars) as reported in

    constant currency
     % of Total Revenue as reported in constant currency % of Total Revenue
    Revenue from Canadian medical cannabis $6,174  9% $6,261  10%
    Revenue from Canadian adult-use cannabis  64,359  100%  57,235  94%
    Revenue from wholesale cannabis  4,173  7%  5,507  9%
    Revenue from international cannabis  12,674  20%  12,191  20%
    Less excise taxes  (23,331) (36)%  (19,945) (33)%
    Total $64,049  100% $61,249  100%
             





    Other Financial Information: Key Operating Metrics

      For the three months ended
      August 31, August 31,
    (in thousands of U.S. dollars)  2025   2024 
    Net beverage revenue $55,739  $55,972 
    Net cannabis revenue  64,511   61,249 
    Distribution revenue  74,007   68,071 
    Wellness revenue  15,244   14,752 
    Beverage costs  34,413   33,050 
    Cannabis costs  41,241   37,054 
    Distribution costs  66,008   60,138 
    Wellness costs  10,370   10,096 
    Adjusted gross profit (excluding PPA step-up) (1)  57,469   59,881 
    Beverage adjusted gross margin (excluding PPA step-up) (1)  38%  41%
    Cannabis adjusted gross margin (excluding PPA step-up) (1)  36%  40%
    Distribution gross margin  11%  12%
    Wellness gross margin  32%  32%
    Adjusted EBITDA (1) $10,181  $9,334 
    Cash and marketable securities (1) as at the period ended:  264,828   280,055 
    Working capital as at the period ended: $433,508  $432,334 
         





    Other Financial Information: Gross Margin and Adjusted Gross Margin      
      For the three months ended August 31, 2025
    (In thousands of U.S. dollars) Beverage Cannabis Distribution Wellness Total
    Net revenue $55,739  $64,511  $74,007  $15,244  $209,501 
    Cost of goods sold  34,413   41,241   66,008   10,370   152,032 
    Gross profit  21,326   23,270   7,999   4,874   57,469 
    Gross margin  38%  36%  11%  32%  27%
               
      For the three months ended August 31, 2024
    (In thousands of U.S. dollars) Beverage Cannabis Distribution Wellness Total
    Net revenue $55,972  $61,249  $68,071  $14,752  $200,044 
    Cost of goods sold  33,050   37,054   60,138   10,096   140,338 
    Gross profit  22,922   24,195   7,933   4,656   59,706 
    Gross margin  41%  40%  12%  32%  30%
    Adjustments:          
    Purchase price accounting step-up  175   —   —   —   175 
    Adjusted gross profit  23,097   24,195   7,933   4,656   59,881 
    Adjusted gross margin  41%  40%  12%  32%  30%
               





    Other Financial Information: Adjusted Earnings Before Interest, Taxes and Amortization

      For the three months ended    
      August 31, August 31, Change % Change
    (In thousands of U.S. dollars)  2025   2024  2025 vs. 2024
    Net income (loss) $1,513  $(34,652) $36,165  (104)%
    Income tax expense (recovery), net  (2,285)  886   (3,171) (358)%
    Interest expense, net  6,696   9,842   (3,146) (32)%
    Non-operating income (expense), net  (3,832)  (12,646)  8,814  (70)%
    Amortization  15,561   31,814   (16,253) (51)%
    Stock-based compensation  5,052   6,917   (1,865) (27)%
    Change in fair value of contingent consideration  (15,000)  —   (15,000) NM
    Project 420 business optimization  200   —   200  NM
    Purchase price accounting step-up  —   175   (175) (100)%
    Litigation costs, net of recoveries  1,007   1,595   (588) (37)%
    Restructuring costs  869   4,247   (3,378) (80)%
    Transaction costs (income), net  400   1,156   (756) (65)%
    Adjusted EBITDA $10,181  $9,334  $847  9%
             
    Other Financial Information: Adjusted Net Income (Loss) Per Share      
      For the three months ended    
      August 31, August 31, Change % Change
       2025   2024  Change
    Net loss attributable to stockholders of Tilray Brands, Inc. $(322) $(39,165) $38,843  (99)%
    Non-operating income (expense), net  (3,832)  (12,646)  8,814  (70)%
    Amortization  15,561   31,814   (16,253) (51)%
    Stock-based compensation  5,052   6,917   (1,865) (27)%
    Change in fair value of contingent consideration  (15,000)  —   (15,000) NM
    Project 420 business optimization  200   —   200  NM
    Litigation costs, net of recoveries  1,007   1,595   (588) (37)%
    Restructuring costs  869   4,247   (3,378) (80)%
    Transaction costs (income)  400   1,156   (756) (65)%
    Adjusted net income (loss) $3,935  $(6,082) $10,017  (165)%
    Adjusted net income (loss) per share - basic and diluted $0.00  $(0.01) $0.01  (100)%
             
    Other Financial Information: Adjusted Free Cash Flow        
      For the three months ended    
      August 31, August 31, Change % Change
    (In thousands of U.S. dollars)  2025   2024  2025 vs. 2024
    Net cash used in operating activities $(1,341) $(35,307) $33,966  (96)%
    Less: investments in capital and intangible assets, net  (9,230)  (6,708)  (2,522) 38%
    Free cash flow $(10,571) $(42,015) $31,444  (75)%
    Add: growth CAPEX  3,009   2,540   469  18%
    Add: cash paid for litigation settlements  2,804   —   2,804  NM
    Adjusted free cash flow $(4,758) $(39,475) $34,717  (88)%
             


    Primary Logo

    Get the next $TLRY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    11/1/2021$18.00 → $11.80Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $TLRY
    SEC Filings

    View All

    SEC Form S-3ASR filed by Tilray Brands Inc.

    S-3ASR - Tilray Brands, Inc. (0001731348) (Filer)

    10/9/25 5:21:32 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Tilray Brands Inc.

    10-Q - Tilray Brands, Inc. (0001731348) (Filer)

    10/9/25 5:12:45 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    10/9/25 7:01:37 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting Continued Growth with Record Q1 Net Revenue of $210 Million and Net Income

    Operational Efficiencies and Focus on Profitability Drove Net Income of $1.5 Million, Adjusted EBITDA Increased 9% to $10 Million and Net Cash Used in Operations Improved by $34 Million Year-Over-Year Canadian Adult-Use Cannabis Gross Revenue Increased 12%, Maintaining the #1 Position in Revenue and Expanding Market Share; International Cannabis Revenue Grew 10% Year-Over-Year Balance Sheet Strengthened to $265 Million in Cash; Net Debt Reduced to $4 Million Reiterates Fiscal Year 2026 Adjusted EBITDA Outlook of $62 Million – $72 Million NEW YORK and LONDON and LEAMINGTON, Ontario, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TL

    10/9/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray, a Global Leader in Medical Cannabis, Announces Expansion of Premium Craft Cannabis Production at its Advanced EU-GMP Facility in Germany; Tilray Medical Enhances Tilray Craft Cannabis Portfolio with New Patient-Centered Offerings

    NEUMÜNSTER, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Medical a division of Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare today announced the expansion of its Tilray Craft portfolio in Germany with five new cannabis flower products produced in Germany at Tilray's EU‑GMP certified facility in Neumünster as part of the BfArM in‑country cultivation program. The additions reflect Tilray's ongoing commitment to providing physicians and pharmacies with a diverse range of quality, EU‑GMP certif

    9/30/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands, Inc. to Announce First Quarter Fiscal Year 2026 Financial Results on October 9, 2025

    NEW YORK and LEAMINGTON, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, today announced that the Company will release its financial results for the first quarter which ended August 31, 2025 before the financial markets open on Thursday, October 9, 2025. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 AM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of Tilray's In

    9/25/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners reiterated coverage on Tilray with a new price target

    Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously

    4/5/24 7:39:50 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Tilray with a new price target

    Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90

    11/2/22 6:37:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray downgraded by The Benchmark Company with a new price target

    The Benchmark Company downgraded Tilray from Hold to Sell and set a new price target of $3.00

    7/29/22 7:19:40 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Simon Irwin D exercised 706,216 shares at a strike of $0.58 and covered exercise/tax liability with 374,295 shares, increasing direct ownership by 7% to 4,826,493 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:07:08 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A exercised 93,928 shares at a strike of $0.58 and covered exercise/tax liability with 49,782 shares, increasing direct ownership by 5% to 920,497 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:42 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 6:52:32 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 3:12:46 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Leadership Updates

    Live Leadership Updates

    View All

    Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA

    ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featuring Terrapin's renowned Wake-n-Bake Beer. This event highlights culinary innovation and fosters community engagement through an array of sweet and savory tastings that showcase the rich flavor

    1/23/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Blue Point Brewing Launches Big Mo Brew to Raise Funds and Awareness for Men's Health During Movember

    PATCHOGUE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island's original craft brewery and subsidiary of Tilray Brands, (NASDAQ:TLRY, TSX:TLRY), is proud to announce the continuation of its men's health awareness campaign in support of Movember. The month shines a light on key men's health issues—mental health, prostate cancer, and testicular cancer—encouraging open conversations and proactive engagement. To honor the initiative, Blue Point Brewing announced the special release of its classic double IPA, Big Mo, available at our brewery and retailers in Long Island, New York. This hazy double IPA, featuring prominent mosaic hops and an ABV of 8.0%, proud

    10/22/24 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Breckenridge Brewery Opens New Location in Fort Collins, Colorado

    FORT COLLINS, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery, a Colorado-based craft brewer with over 30 years of experience brewing approachable, well-balanced beers, announces the opening of its new brewery location in Fort Collins. With doors opening in early August 2024, the new 10,000-square-foot Breckenridge Brewery offers a full restaurant experience and a new vibrant atmosphere in the heart of Fort Collins for all to enjoy. The new location will be a full-service restaurant, upholding the Breckenridge Brewery legacy while ushering in new opportunities for innovation and community collaboration. With a menu boasting a diverse range of culinary delights designed to co

    8/5/24 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Financials

    Live finance-specific insights

    View All

    Tilray Brands, Inc. to Announce First Quarter Fiscal Year 2026 Financial Results on October 9, 2025

    NEW YORK and LEAMINGTON, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, today announced that the Company will release its financial results for the first quarter which ended August 31, 2025 before the financial markets open on Thursday, October 9, 2025. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 8:30 AM Eastern Time on the same day. The webcast can be accessed on the Events & Presentations section of Tilray's In

    9/25/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results

    Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2nd Highest in the Company's History International Cannabis Revenue Increased 71% in Q4 and 19% for the Fiscal Year; Canadian Cannabis Remained #1 by Revenue in the Fiscal Year; Global Cannabis Gross Margin Increased by ~700 Basis Points in the Fiscal Year 19% Revenue Growth in Tilray Beverages with $241 Million for the Fiscal Year 9% Revenue Growth in Tilray Wellness with $60 Million for the Fiscal Year Strong Balance Sheet with $256 Million Available in Cash and Marketable Securities; Total Debt Repayments of ~$100 Milli

    7/28/25 4:30:13 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025

    NEW YORK and LEAMINGTON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the fourth quarter and full fiscal year ended May 31, 2025, after market close on Monday, July 28, 2025. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 4:30 PM Eastern Time. The webcast can be accessed on the Events & Presentations section of Tilray's Investor Relations websi

    7/9/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Tilray Brands Inc. (Amendment)

    SC 13G/A - Tilray Brands, Inc. (0001731348) (Subject)

    2/13/23 1:34:44 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Tilray Brands Inc.

    SC 13G - Tilray Brands, Inc. (0001731348) (Subject)

    2/10/23 4:41:36 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Tilray Brands Inc.

    SC 13D - Tilray Brands, Inc. (0001731348) (Filed by)

    7/22/22 4:30:22 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care